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INTRODUCTION
Pyruvate kinase (PK) deﬁciency in Basenji dogs is asso-
ciated with severe hemolytic anemia. Affected dogs suffer
from chronic, regenerative, hemolytic anemia with hemat-
ocrits of 18% to 27% (median, 20%). 51Cr-tagged red
blood cell survival, which in normal dogs averages 1 month,
is shortened to a few days [1,2]. PK-deficient dogs have
high in vitro erythrocyte PK activity caused by the expres-
sion of the M2-type PK isoenzyme (encoded by the PK-M
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ABSTRACT
Severe hemolytic anemia in Basenji dogs secondary to pyruvate kinase (PK) deficiency can be corrected by marrow
allografts from healthy littermates after a conventional high-dose myeloablative conditioning regimen. The nonmye-
loablative conditioning regimen used here, which consisted of a sublethal dose of 200 cGy total body irradiation
before and immunosuppression with mycophenolate mofetil and cyclosporine after a dog leukocyte antigen (DLA)-
identical littermate allograft, has been found to be effective in establishing stable mixed donor/host hematopoietic
chimerism in normal dogs. We explored the feasibility of nonmyeloablative marrow allografts for the treatment of
canine PK deficiency and studied the effect of stable allogeneic mixed hematopoietic chimerism on the natural course
of the disease. Five affected dogs received transplants, of which 3 dogs had advanced liver cirrhosis and myelofibrosis.
Both complications were presumed to be due to iron overload. All 5 dogs showed initial engraftment. Two rejected
their grafts after 6 weeks but survived with complete autologous marrow recovery and return of the disease. One dog
died from liver failure on day 27 with 60% donor engraftment. Two dogs have shown sustained mixed donor/host
chimerism for more than a year with 85% and 12% donor hematopoietic cells, respectively. Overall clinical response
correlated with the degree of donor chimerism. The dog with the low degree of chimerism achieved partial resolu-
tion of hemolysis, but the disease symptoms persisted as manifested by increasing iron overload resulting in progression
of marrow and liver fibrosis. The dog with the high degree of donor chimerism achieved almost complete resolution
of hemolysis with a decrease of marrow iron content and resolution of marrow fibrosis. These observations suggest
that mixed hematopoietic chimerism can be relatively safely established in dogs with PK deficiency even in the pres-
ence of advanced liver cirrhosis. However, although effective in correcting or delaying the development of myelofi-
brosis, a low degree of mixed chimerism was not sufficient to prevent continued hemolysis of red blood cells of host
origin. Complete donor chimerism appears necessary to achieve a long-term cure.
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gene), which is normally present in all tissues during fetal
life and remains the major isoenzyme in the erythroid pre-
cursors [3,4]. They lack the normal R-type isoenzyme
(encoded by the PK-L gene), which begins to appear in nor-
mal erythrocytes as erythroid maturation proceeds [5]. The
expression of the M2-type isoenzyme is thought to be a
compensatory change due to R-type PK deficiency; how-
ever, it does not prevent hemolysis in vivo [4]. PK-deﬁcient
dogs experience shortened life spans due to both progres-
sive myelofibrosis ending in osteosclerosis [6,7] and liver
cirrhosis. Both complications are thought to be related to
severe hemosiderosis, although the precise pathophysio-
logic relationships are not certain. In the 1970s, it was
shown that marrow allografts from healthy littermates after
a high-dose conditioning regimen consisting of a single
dose of 920 cGy total body irradiation (TBI) in 3 young
PK-deﬁcient dogs resulted in the long-term establishment
of normal hematopoiesis [8]. During more than 5 years of
follow-up, none of the marrow recipients developed
osteosclerosis, which is an otherwise inevitable long-term
complication in untreated PK-deﬁcient dogs. Furthermore,
the iron overload present before transplantation gradually
decreased over time, and the development of liver cirrhosis
was avoided [8].
When the cure of severe canine hereditary hemolytic
anemia by conventional marrow allografts was observed—
in particular, when iron overload was reversed and liver cir-
rhosis was avoided—the stage was set for the ﬁrst successful
allograft in a human patient with thalassemia major after
conditioning with high-dose dimethylbusulfan and
cyclophosphamide [9]. The principal role assigned to
dimethylbusulfan was to eradicate the underlying disease
and create marrow space, whereas that of cyclophos-
phamide was to provide host immunosuppression [10-13].
Subsequently, marrow allografts after high-dose busulfan
and cyclophosphamide have been used successfully to treat
not only patients with thalassemia major [14], but also
patients with other red blood cell disorders such as sickle
cell disease [15,16] and a severe form of PK deficiency
[17]. However, the risks of regimen-related mortality and
toxicity coupled with the availability of transfusion and
chelation therapies have made physicians hesitant to use
this approach widely in patients with red blood cell disor-
ders except for those with high-risk factors [18-21].
Two recent observations have prompted us to take a
renewed look at the canine model of severe hereditary
hemolytic anemia. The first has been that some human
patients with thalassemia major and sickle cell disease who
have undergone conventional transplantation have shown
stable mixed chimerism, and yet have remained free of
symptoms from their underlying diseases [15,22,23]. The
second observation involved the development of a new
transplantation regimen in the canine model that had little
toxicity and resulted in stable donor/host hematopoietic
chimerism. This new approach challenged the concept that
a myeloablative preparative regimen was needed for creation
of marrow space for donor cells to engraft, particularly
because stable mixed chimerism could also be established in
dogs in which low-dose irradiation to cervical, thoracic, and
upper abdominal lymph nodes was substituted for TBI [24].
The TBI regimen involved a sublethal dose of 200 cGy fol-
lowed by a combination of 2 synergistic immunosuppressive
agents, mycophenolate mofetil (MMF) and cyclosporine
(CSP), after dog leukocyte antigen (DLA)-identical litter-
mate marrow transplantation [25]. This nonmyeloablative
regimen has been successfully translated into the clinic,
where it has been used to treat older or medically infirm
patients with hematologic malignancies and nonmalignant
diseases in the outpatient setting [26,27]. The present pilot
study explored the feasibility of nonmyeloablative marrow
allografts in the treatment of PK deficiency. It involved
5 affected dogs, of which 2 were young and 3 were 5 to
5.5 years old and had advanced marrow fibrosis and liver
cirrhosis. Specific questions addressed were the safety of
this approach in the setting of liver cirrhosis, the feasibil-
ity of establishing stable allogeneic mixed hematopoietic
chimerism, and the effect of mixed chimerism on the natural
history of canine PK deﬁciency.
MATERIALS AND METHODS
Dogs
Five PK-deficient Basenji dogs and their respective
healthy littermates were obtained from the colony at the
Scott-Ritchey Research Center, Auburn University, Alabama.
Two of the PK-deﬁcient dogs were 6 months old, and the
remaining 3 were 5, 5, and 5.5 years old, respectively. PK-
deﬁcient dogs weighed from 8 to 9.5 kg (median 8.2 kg). All
study dogs were immunized for leptospirosis, papillo-
mavirus, distemper, hepatitis, and parvovirus. None of the
PK-deficient dogs had received blood transfusions before
transplantation. Research was conducted according to the
principles outlined in the Guide for Laboratory Animal Facil-
ities and Care prepared by the National Academy of Sciences,
National Research Council. The research protocols were
approved by the Institutional Animal Care and Use Commit-
tees of the Fred Hutchinson Cancer Research Center and the
College of Veterinary Medicine, Auburn University.
Littermate donor-recipient pairs were chosen on the
basis of identity by highly polymorphic major histocompati-
bility complex class I and II microsatellite markers [28]. In
addition, specific DLA-DRB1 allelic identity was deter-
mined by direct sequencing [29].
PK Genotype Assessment
The PK phenotype was confirmed by genetic testing
according to the method published by Whitney et al. [3,30].
The PK activity assay was performed by the method of
Beutler [31], which involves measuring the decrease in
absorbance of reduced nicotinamide adenine dinucleotide at
340 nm in a coupled reaction with lactate dehydrogenase.
Absorbance was measured over 3 minutes using a recording
spectrophotometer. Results were expressed as units of activ-
ity per gram of hemoglobin. The PK activity tested in 2 dogs
before transplantation was elevated.
PK isoenzyme expression was measured by Western blot
analysis performed as previously described [3]. Briefly,
hemolysates (100 µg protein) separated by sodium dodecyl
sulfate polyacrylamide gel electrophoresis were electroblot-
ted to nitrocellulose membranes. The membranes were
washed with Tris-buffered saline plus Tween 20 (TBST)
(10 mmol/L Tris HCL, pH 8.0, 150 mmol/L NaCl, 0.05%
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Tween 20), incubated in blocking buffer (1% bovine serum
albumin and 1% goat serum in TBST), and washed twice
with TBST before being incubated with 1 µg/mL anti-L-
type PK antibody. Blots were washed 3 times in TBST and
developed with Supersignal ULTRA chemiluminescent
substrate (Pierce, Rockford, IL) using goat anti-rabbit
horseradish peroxidase following the manufacturer’s proto-
col (Santa Cruz Biotechnology, Santa Cruz, CA).
Supportive Care
Marrow for transplantation was aspirated from the
donors under general anesthesia through long needles
inserted into humeri and femora [32]. Recipients were given
a single dose of 200 cGy TBI delivered at 7 cGy/min from
2 opposing 60Cobalt sources [33]. Marrow was infused intra-
venously at doses of 1.1 to 2.7  108 cells/kg (median 2.17
 108 cells/kg) within 4 hours of TBI. The day of marrow
grafting was designated as day 0. Recipients were given
15 mg/kg CSP twice daily orally on days –1 to 35 and
10 mg/kg MMF twice daily subcutaneously on days 0 to 27
after transplantation. They were given standard postgrafting
care that included oral nonabsorbable antibiotics 3 times
daily, neomycin sulfate and polymyxin sulfate combined
with systemic enroﬂoxacin, which were administered from
day –5 until the day of white blood cell count recovery to
>1,000/µL. Red blood cell and platelet transfusions from
unrelated donors were given clinically as indicated. All
blood products were irradiated in vitro with 2200 cGy from
a 137cesium source. The dogs’ clinical status was assessed
twice daily. Liver biopsies were obtained through the skin
under general anesthesia using standard biopsy needles.
Dogs that died or were euthanized underwent complete
necropsy with histological examination of tissue specimens.
Engraftment and Chimerism Studies
Marrow engraftment was assessed by sustained recover-
ies of granulocyte and platelet counts after the postirradia-
tion nadirs, by histologic features of the marrow from
biopsy or autopsy specimens, and by documentation of
donor cells in the marrow (including red blood cell precur-
sors) and among granulocytes and mononuclear cells from
the peripheral blood using polymorphic microsatellite
markers in a polymerase chain reaction–based assay [34].
The microsatellite marker technique detected between
2.5% and 97.5% mixtures of donor and host cells [34].
Graft rejection was defined as disappearance of cells of
donor origin and exclusive presence of host-type cells.
Peripheral blood cells were separated by Ficoll-hypaque
density gradient. Red blood cell precursors were obtained
through cell sorting (Vantage, Becton Dickinson, San Jose,
CA) on CD45-negative/dim and CD71-positive cells, which
represented cells at an intermediate stage of erythroid devel-
opment [35]. Canine CD45 antibody (CA12.10C12) was
obtained from P.F. Moore (University of California, Davis,
CA). The CD71 antibody against the human transferrin
receptor (DAKO, Carpinteria, CA) stains canine marrow
cells, which give rise to burst-forming units-erythroid
(BFU-E) colony-forming cells (data not shown). Mixed
hematopoietic chimerism was quantiﬁed by estimating the
proportion of donor-speciﬁc DNA among host DNA using
the storage phosphor imaging technique [36].
Assessment of Treatment Effect
Correction of disease manifestations after transplanta-
tion was assessed by evaluating hematocrits and reticulocyte
values, erythrocyte PK activity, expression of R-type isoen-
zyme in the mature erythrocytes, marrow or liver iron stor-
age, and marrow and liver ﬁbrosis. Complete resolution of
hemolysis was defined as normalization of reticulocyte
counts, hematocrits, and marrow myeloid-to-erythroid
ratios. Partial response was considered when 2 criteria were
met: ≥50% increase in hematocrit and ≥50% reduction in
reticulocyte counts. Lack of response was defined as no
change or progression in these parameters from the pre-
treatment values. Tissue iron concentration was determined
on fresh or frozen samples by bichromatic endpoint using a
Dupont Dimension Analyzer [37]. Liver samples were
stained with hematoxylin, eosin V, and periodic acid shift.
Gomori’s trichrome stain was used for fibrosis evaluation.
Marrow fibrosis was classified as grades 1 (25% fibrosis),
2 (50% fibrosis), 3 (75% fibrosis), and 4 (100% fibrosis)
[38]. Liver ﬁbrosis was graded by the following stages: 0, none;
1, mild; 2, moderate; and 3, severe (cirrhotic).
RESULTS
Clinical Status of Dogs Before Transplantation
Table 1 summarizes pretransplantation characteristics of
PK-deficient dogs. All of them had evidence of chronic
hemolysis with hematocrits ranging from 15.2% to 30.3%
(median, 23.4%) and reticulocyte counts ranging from
13.9% to 29.7% (median, 15.9%). Bilirubin levels ranged
from 0.1 to 1 mg/dL (median 0.3 mg/dL). Liver enzymes
revealed slightly elevated levels (median, 1.5-fold) of aspar-
tate aminotransferase (AST), alanine aminotransferase
(ALT), and alkaline phosphatase (AP) in 2 of the older dogs
(E592 and E679). Liver biopsies revealed advanced hemo-
siderosis and sclerosis in these 2 dogs. These 2 older dogs
also suffered from another independently segregating auto-
somal recessive disease, immunoproliferative small bowel
disease, and they required dietary restriction and Metron-
idazole treatment [39].
Nonhematopoietic Toxicities and Graft-Versus-Host
Disease
In general, the transplantation regimen was well toler-
ated. Dogs did not require parenteral nutritional support.
There was no evidence of diarrhea or other gastrointestinal
signs of toxicity in the 3 dogs not suffering from lymphopro-
liferative small bowel disease. All 3 dogs with liver cirrhosis
showed increases in serum bilirubin and liver enzyme levels,
which appeared to be related to high CSP blood levels. In 2
of the 3 dogs, liver enzymes returned to pretransplantation
levels after the CSP dosage was reduced, whereas 1 dog
(E679) developed fulminant liver failure and died on day 27.
No other toxicities were seen. None of the dogs developed
acute or chronic graft-versus-host disease (GVHD) (Table 2).
Hematopoietic Engraftment
All 5 recipients showed initial allogeneic engraftment.
Figures 1 and 2 illustrate both the hematologic changes and
the results of microsatellite marker studies in 4 of the 5 dogs.
Not shown are the data on the 5.5-year-old dog (E679) that
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died on day 27 from liver failure with 60% donor hemato-
poietic cells. Two animals (E569 and E677) had evidence of
donor engraftment for 6 weeks but subsequently rejected
their grafts and recovered autologous marrow function with
return of signs and symptoms of PK deﬁciency. The 2 other
dogs (E592 and E675) had sustained stable mixed chimerism
for 53 and 81 weeks with median contributions of 85% and
12% of donor cells, respectively, in the peripheral blood.
The hematologic toxicities of the transplantation regi-
men were mild. The median granulocyte nadir for the
5 dogs was 980/µL and occurred on day 14. The median
number of days with granulocyte counts <500/µL was 0
(range, 0-2 days). Granulocyte recoveries (granulocyte
count > 3500/µL) were prompt and completed between days
29 and 41 (Figures 1 and 2). The platelet nadirs were
reached between days 13 and 18, with a median nadir of
7000/µL. The median number of days with platelet counts
<10,000/µL was 1 (range, 0-7 days). Platelet recoveries
(counts > 160,000/µL) were also prompt and completed
between days 32 and 48. The percentages of reticulocytes,
elevated in all dogs before transplantation (median, 15.9%),
decreased to almost 0% during the first week after trans-
plantation. At that time, all recipients required red blood
cell transfusions to keep their hematocrits above 20%. The
median number of transfused 100 mL whole blood units was
6 (range, 4-6). Reticulocyte counts increased again in all
dogs between 32 and 46 days. In 2 dogs (E592 and E675)
with stable mixed hematopoietic chimerism, reticulocytosis
was transient, followed by normalization of hematocrits,
consistent with the appearance of normal donor red blood
cells in the peripheral blood (Figure 1). In contrast, in the
2 dogs that rejected the grafts (E569 and E677), reticulocy-
tosis persisted without normalization of the hematocrit (Fig-
ure 2), indicating the continued presence of defective host
red blood cells and lack of normal donor red blood cells.
On day 30, dog E569 had up to 60% donor hemato-
poietic cells, but with the episode of graft refection, experi-
enced a decrease in granulocyte counts to 160/µL and in
platelet counts to 5000/µL on day 40, followed by complete
autologous recovery by day 57. This pattern of cytopenia
Table 1. Pretransplantation Characteristics of 5 PK-Deﬁcient Dogs*
Degree of Fibrosis¶ PK Enzyme
Dog Age, HTC, Reticulocytes, Bilirubin Liver Enzymes Liver Marrow Iron, µg/g# Activity,
Number mo %† %‡ mg/dL§ [AST/ALT/AP], U/L (range, 0-3) (range, 0-4) Liver Marrow U/g Hb**
E569 60 12.8 14.8 0.1 80/28/86 NA 2 NA NA NA
E592 60 23.4 29.7 1.0 158/81/172 2 2 22,720 2577 9.9
E675 6 29.7 13.9 0.1 85/36/136 NA 0 NA 169 6.9
E677 6 28.6 25.1 0.3 65/41/124 NA 0 NA 711 NA
E679 65 21.7 15.9 0.4 77/129/190 3†† 2 48,058†† 3577 NA
*PK indicates pyruvate kinase; HTC, hematocrit; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AP, alkaline phosphatase;
Hb, hemoglobin; NA, not available.
†Normal values for dogs are 37% to 54% [58].
‡Normal values for dogs are 0.0% to 1.0% [58].
§Normal values for dogs are 0.0 to 0.3 mg/dL [58].
Normal values for dogs are 16 to 43 U/L for AST; 15 to 58 U/L for ALT; and 10 to 73 U/L for AP [58].
¶Marrow ﬁbrosis was classiﬁed as grades 1 (25% ﬁbrosis), 2 (50% ﬁbrosis), 3 (75% ﬁbrosis), and 4 (100% ﬁbrosis) [38]. Liver ﬁbrosis was graded
by the following stages: 0, none; 1, mild; 2, moderate; and 3, severe (cirrhotic).
# Normal values obtained from 6 control dogs are 700 to 1400 µg/g for liver and 130 to 350 µg/g for marrow.
**Normal values for dogs are 2.4 to 3.6 U/g Hb [30].
††Liver sample was obtained 4 weeks after transplantation.
Table 2. Marrow Grafts From DLA-Matched Littermates in 5 PK-Deficient Recipients Given 200 cGy TBI Followed by Immunosuppression With
MMF and CSP*
Number of Duration Maximum % of
Dog Marrow Cells, Sustained of Mixed Donor Cells Among Acute/Chronic
Number 108/kg Allograft Chimerism, wk White Blood Cells Graft Rejection GVHD Comments
E569 2.17 No 6 60 Yes No/No ET2 at week 13
E592 2.2 Yes 53 95 No No/No ET1 at week 53†
E675 1.13 Yes >81 50 No No/No Alive at >81 weeks
E677 2.7 No 6 5 Yes No/No Alive at >81 weeks
E679 1.88 Yes 4 60 No No/No ET1 at week 4‡
*DLA indicates dog leukocyte antigen; PK, pyruvate kinase; TBI, total body irradiation; MMF, mycophenolate mofetil; CSP, cyclosporine;
GVHD, graft-versus-host disease; ET2, euthanized at completion of the study; ET1, euthanized because of poor clinical condition.
†Liver failure.
‡Liver and renal failure.
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was not seen in the other dog (E677) that rejected the graft,
which showed a maximum of only 5% donor hematopoietic
cells (Figure 2).
Stable Mixed Donor/Host Chimerism
Two dogs (E592 and E675) had stable allogeneic
engraftment with median donor contributions among nucle-
ated peripheral blood cells of 85% and 12%, respectively.
Their posttransplantation data are summarized in Tables 3
and 4 and in Figure 1.
The hematopoietic cells of dog E592 were predomi-
nantly of donor origin. The maximum donor contribution in
hematopoiesis (85%-90%) was seen at week 5 after trans-
plantation, and this percentage remained stable throughout
the period of follow-up. The donor contribution to ery-
throid precursors was 65% and to granulocytes was 95%.
Expression of the normal R-type PK isoenzyme in mature
red cells was about 50%. Clinically, this dog experienced
complete resolution of hemolysis. The hematocrit normal-
ized to 40.2%, and the reticulocyte count declined to 1.3%.
Figure 1. Peripheral blood granulocyte, platelet, hematocrit, and reticulocyte changes in 2 pyruvate kinase–deﬁcient dogs (E592 and E675) with
stable mixed donor/host hematopoietic chimerism after conditioning with 200 cGy total body irradiation (TBI) followed by receipt of marrow grafts
from dog leukocyte antigen–identical littermates and posttransplantation mycophenolate mofetil (MMF)/cyclosporine (CSP) for 4 and 5 weeks, respec-
tively. The bottom panels show the results of testing for microsatellite markers of recipient and donor cells before transplantation (lanes 1 and 2) and
recipient cells after marrow transplantation (lanes 3 to 24). G indicates granulocytes; MNC, mononuclear cells.
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The marrow at 8 months after transplantation showed a
myeloid-to-erythroid ratio of 3:1 compared with 1:3 before
transplantation. Also, the marrow fibrosis present before
transplantation completely resolved (Figure 3). Marrow
hemosiderosis was still present, but marrow iron content had
decreased by about 50% (Table 3). In vitro erythrocyte PK
activity, elevated before transplantation, decreased from 9.9
to 5.3 U/g hemoglobin (Hb) after transplantation but was
still above the normal range. Liver enzymes remained ele-
vated after transplantation, consistent with persistent liver
disease. Given the progressive liver cirrhosis, the dog was
euthanized 53 weeks after transplantation. Indeed, histologic
examination of the liver revealed progression of ﬁbrosis from
grade 2 before transplantation to grade 3 and an increase in
liver iron content from 22,720 µg/g before transplantation to
37,413 µg/g. We found it interesting that dog E592’s
immunoproliferative small bowel disease went into remis-
sion. The dog was on a normal diet, and Metronidazole ther-
apy was discontinued.
In dog E675, the maximum donor contribution to
hematopoiesis (50%) was seen at week 4 after transplantation.
Thereafter, the percentage of donor cells gradually decreased
Figure 2. Peripheral blood granulocyte, platelet, hematocrit, and reticulocyte changes in 2 pyruvate kinase–deﬁcient dogs with graft rejection
(E569 and E677) after conditioning with 200 cGy total body irradiation (TBI) followed by receipt of marrow grafts from dog leukocyte
antigen–identical littermates and posttransplantation mycophenolate mofetil (MMF)/cyclosporine (CSP) for 4 and 5 weeks, respectively. The bot-
tom panels show the results of testing for microsatellite markers of recipient and donor cells before transplantation (lanes 1 and 2) and recipient cells
after marrow transplantation (lanes 3 to 16). G indicates granulocytes; MNC, mononuclear cells.
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to 30% at week 12 and 12% at week 24 after transplantation,
where it has remained now beyond 81 weeks. The donor con-
tribution to erythroid precursors was 30% at week 12 and
14% at week 81 after transplantation, comparable to the
donor percentages among other nucleated marrow cells. This
dog achieved a partial resolution of hemolysis. His hematocrit
increased to 40.2%, and reticulocyte levels declined from
13.9% to 7.1% at week 12 after transplantation. However, at
12 weeks after transplantation, the marrow remained hyper-
cellular with a myeloid-to-erythroid ratio of 1:2 and marked
hemosiderosis. Iron content in the marrow increased from
169 µg/g before transplantation to 281 µg/g. Erythrocyte PK
activity normalized, decreasing from 6.9 U/g Hb before to
3.2 U/g Hb after transplantation.
At week 54 after transplantation, this dog (E675)
showed a decrease in hematocrit to 31.7% and an increase
in reticulocytes to 15.6%, consistent with recurrence of
clinical symptoms of hemolysis. Marrow studies revealed a
marked increase in cellularity with persistence of the
reversed myeloid-to-erythroid ratio (1:2)—the same as that
at 3 months, but without evidence of fibrosis. Hemolysis
persisted, but the hematocrit at week 81 after transplan-
tation remained higher than before transplantation (34.4%).
The reticulocyte level was 9.4%. Expression of the normal
R-type PK isoenzyme in mature red cells was more than
50% as assessed by Western blot (data not shown). Marrow
studies performed at that time still showed increased cellu-
larity with persistence of the reversed myeloid-to-erythroid
ratio (1:2). Early small foci of ﬁbrosis were noted. Marrow
iron content had increased to 1688 µg/g. Erythrocyte PK
activity was elevated at 7.4 U/g Hb.
The dog showed an increase in alkaline phosphatase to
231 U/L, up from 136 U/L before transplantation. A liver
biopsy performed 12 months after transplantation showed
early signs of ﬁbrosis and marked hemosiderosis consistent
with persistent iron deposition.
DISCUSSION
Canine hereditary hemolytic anemia due to PK defi-
ciency characteristically results in the development of liver
cirrhosis and severe myeloﬁbrosis, both thought to be due
to iron overload. In a previous study using young PK-
deficient dogs, we showed that marrow transplantations
from healthy littermates after high-dose TBI resulted in all-
donor hematopoietic chimerism, prevention of both liver
cirrhosis and myeloﬁbrosis, and even reversal of the hepatic
iron overload over several years [8]. The observations on
reversal of iron overload and prevention of liver cirrhosis
paved the way for clinical application of marrow transplan-
tation to the treatment of patients with other red blood cell
disorders, such as thalassemia major and sickle cell disease.
Although, on the whole, transplantations for these diseases
have been successful, the high-dose conditioning regimens
used have many short- and long-term toxicities, particularly
in patients with preexisting liver disease [40-43]. The toxici-
ties associated with conventional transplantations prompted
the current pilot study in PK-deﬁcient dogs, which explored
marrow grafts using a novel nontoxic transplantation regi-
men. The results allowed several conclusions.
First, the regimen was generally well tolerated except for
1 of the 3 older dogs with advanced liver cirrhosis, which suc-
cumbed to hepatic failure about a month after transplanta-
tion. This was likely an avoidable complication, attributable
to unusually high CSP serum levels (>1500 ng/mL), which
could have been corrected by adjustment of CSP dosage. The
Table 3. Data in 2 Dogs With Stable Mixed Donor/Host Chimeras* 
Weeks Liver PK Expression
After Reticulo- Resolution Enzymes Degree of Fibrosis¶ Enzyme of R-Type PK
Dog Trans- HTC, cytes, of Bilirubin, [AST/ALT/AP], Liver Marrow Iron, µg/g# Activity, Isozyme
Number plantation %† %‡ Hemolysis mg/dL§ U/L (range, 0-3) (range, 0-4) Liver Marrow U/g Hb** % of normal
E592 53 39.3 1.3 PR 0.2 100/36/178 3 0 37,413 1233 5.3 25–50
E675 81 38.4 9.4 PR 0.2 35/42/231 0-1 0-1 NA 1688 7.4 50–70
*HTC indicates hematocrit; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AP, alkaline phosphatase; PK, pyruvate kinase;
Hb, hemoglobin; PR, partial response; NA, not available.
†Normal values for dogs are 37% to 54% [58].
‡Normal values for dogs are 0.0% to 1.0% [58].
§Normal values for dogs are 0.0 to 0.3 mg/dL [58].
Normal values for dogs are 16 to 43 U/L for AST; 15 to 58 U/L for ALT; and 10 to 73 U/L for AP [58].
¶Marrow ﬁbrosis was classiﬁed as grades 1 (25% ﬁbrosis), 2 (50% ﬁbrosis), 3 (75% ﬁbrosis), and 4 (100% ﬁbrosis) [38]. Liver ﬁbrosis was graded
by the following stages: 0, none; 1, mild; 2, moderate; and 3, severe (cirrhotic).
#Normal values obtained from 6 control dogs are 700 to 1400 µg/g for liver and 130 to 350 µg/g for marrow.
**Normal values for dogs are 2.4 to 3.6 U/g Hb [30].
Table 4. Contributions of Donor Cells Among Peripheral Blood and 
Marrow Cell Subpopulations From 2 Long-Term Survivors After Marrow
Allografts
Donor Contributions, %
Peripheral Blood Bone Marrow
Dog Mononuclear All Nucleated Erythroid
Number cells Granulocytes Cells Precursors
E592 60* 95* 90† 65†
E675 11* 12* 13‡ 14‡
*53 weeks after transplantation. 
†36 weeks after transplantation.
‡81 weeks after transplantation.
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regimen-related pancytopenias were mild and brief, with
granulocyte nadirs ranging from 480/µL to 1840/µL and
platelet nadirs ranging from 5000/µL to 19,000/µL.
Second, 2 of 4 evaluable dogs eventually rejected their
grafts. In 1 of the 2, rejection might have been caused by very
low CSP serum levels due to “noncompliance” with the liquid
oral CSP formula used in that dog. Subsequently, this prob-
lem was addressed by switching to encapsulated CSP. The
second rejection was likely due to the fact that 200 cGy TBI
was at the threshold of immunosuppression needed for allo-
geneic engraftment. Rejection was also seen in 1 of 12 previ-
ously reported normal dogs that underwent transplantation
with the currently used regimen [25,44] but in none of 3 PK-
deﬁcient dogs that subsequently underwent transplantation
(A. Takatu, J.M.Z., M.T. Little, R.S., unpublished data, 2000).
Pooling the results in current and subsequent PK-deﬁcient
dogs, we observed 2 rejections among 7 dogs that received
transplants, a result that was not statistically signiﬁcantly dif-
ferent from 1 rejection among 12 normal dogs that received
transplants (P = .26 by exact simulation test) [45]. Neverthe-
less, rejections in this and previous studies were nonfatal, and
dogs returned to status quo, even though in 1 dog complete
autologous recovery was preceded by a 2.5-week period of
renewed pancytopenia. Maximum donor engraftment before
rejection was 60%. Graft rejection can likely be overcome by
either including additional nontoxic immunosuppression
before transplantation—for example, cytotoxic T lympho-
cyte–associated antigen-4 immunoglobulin (CTLA4-Ig)
[46]—or by increasing the number of transplanted donor
hematopoietic cells [47-50].
Third, 2 of the 4 evaluable dogs had established stable
mixed donor-host chimeras without GVHD, even though all
immunosuppression was discontinued after day 35. Mixed
chimerism involved all hematopoietic lineages. This was con-
sistent with ﬁndings in otherwise healthy dogs in which stable
mixed chimerism lasting for years has been observed [25].
Fourth, improvement of clinical status seemed to corre-
late with the degree of donor contribution to hematopoiesis.
Hematocrit values and reticulocyte counts in dog E592 with
>60% of donor cells normalized and remain stable. In con-
trast, in dog E675, which initially showed 30% to 50% of
donor engraftment, hematocrit values and reticulocyte
counts improved initially but subsequently declined as donor
chimerism decreased to a steady level of 10% to 14%. These
findings are in keeping with reports from mixed chimeric
thalassemic patients after conventional allografts showing a
recurrent need for transfusions only in patients with low
(<25%) contributions of donor cells to hematopoiesis [23,51-
53]. Decreases in erythrocyte PK activity observed in those
2 dogs have to be interpreted with caution because the
ranges of erythrocyte PK activities of affected dogs overlap
with those of normal dogs [30]. However, one may speculate
that the decline in PK activity after transplantation resulted
from a decrease in the number of defective host erythrocytes
with a high PK activity from the M2 isoenzyme and the
appearance of donor erythrocytes with the normal R-type
PK isoenzyme and normal PK activity. Indeed, in both dogs
we were able to detect expression of the normal R-type PK
isoenzyme in mature red blood cells after transplantation. In
dog E592, R-type PK isoenzyme expression was about 50%
of that seen in a normal dog, indicating the presence of at
least 50% of normal donor red blood cells in the peripheral
blood, similar to the percentages of donor contribution
among red blood cell precursors in the marrow. In dog E675,
with only 15% of donor cells among red blood cell precur-
sors in the marrow, the R-type PK isoenzyme expression was
more than 50%, indicating the enrichment of donor red
blood cells in the peripheral blood. These results are consis-
tent with the ﬁndings reported in thalassemia patients with
persistent mixed chimerism after conventional marrow trans-
plantation [53] and with those in -thalassemic mice, sug-
gesting that red blood cells originating from small numbers
of transplanted normal donor cells dominated over defective
host cells in stable chimeras [54].
We had anticipated that the longer-lived donor red
blood cells would persist and predominate in the peripheral
blood, thereby reducing the need for production of short-
lived host red blood cells. Indeed, in dog E675, with a low
degree of donor chimerism among red blood cell precur-
sors, we observed some enrichment of donor red blood cells,
which resulted in an increase of hematocrit. However, mar-
row erythropoiesis remained increased with elevated
reticulocyte counts, and the dog continued to hemolyse and
disease symptoms progressed. In contrast, in dog E592, with
a higher degree of donor chimerism, the contribution of
donor cells in mature red blood cells was similar to that seen
Figure 3. Marrow histology from a pyruvate kinase–deﬁcient dog with
stable mixed chimerism (E592) before (A) and 8 months after (B)
receipt of graft from a dog leukocyte antigen–identical littermate. Of
note, grade 2 marrow ﬁbrosis was seen before transplantation but com-
pletely resolved after transplantation. Marrow biopsies were stained
with Gomori’s trichrome. Original magniﬁcation 100. 
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among red blood cell precursors. This degree of donor
chimerism was sufﬁcient to achieve clinically an apparently
complete resolution of hemolysis with normalization of
marrow erythropoiesis, clearance of marrow fibrosis, and
decrease of marrow iron content. However, lack of a nor-
malization of R-type isoenzyme expression among mature
erythrocytes indicated that defective host cells were still
produced and hemolysed. It is likely that complete donor
chimerism may be necessary to change the natural course of
PK-deficiency disease, similar to what was accomplished
previously in dogs conditioned with high-dose TBI [8].
Fifth, the severe marrow ﬁbrosis present in the 5.5-year-
old dog with stable mixed chimera and high donor-cell
percentages completely resolved by 32 weeks after trans-
plantation, and the marrow iron content decreased. In
contrast, the younger dog with mixed chimera and low
donor-cell percentages that underwent transplantation
without detectable marrow ﬁbrosis showed increased mar-
row hemosiderosis and early signs of ﬁbrosis 81 weeks after
transplantation. These ﬁndings suggest that active marrow
deposition of iron contributes to the pathogenesis of
myeloﬁbrosis in PK-deﬁcient dogs.
Finally, both dogs showed a progression of liver
hemosiderosis and fibrosis, with advancing liver failure in
dog E592. It is unclear why this dog’s liver iron content
and fibrosis progressed, whereas its marrow iron content
decreased and marrow fibrosis resolved. However, this
dog already had progressive liver disease at the time of
transplantation.
Our ﬁndings indicate that the conversion of mixed to all-
donor chimerism may be needed when using hematopoietic
cell transplantation for the treatment of hemolytic diseases.
Observations in patients who have relapsed with chronic mye-
locytic leukemia after conventional marrow transplantations
[55,56], in a patient treated with a conventional transplanta-
tion for thalassemia [23], and in dogs given nonmyeloablative
marrow grafts [57] have shown that conversion from mixed to
all-donor chimerism can be accomplished by infusion of
donor lymphocytes. In contrast to the setting of hemolytic
anemia, mixed chimerism might be expected to correct disease
manifestations in patients with sickle cell disease, in whom
transfusions of normal red blood cells can avert disease mani-
festations. This expectation has been conﬁrmed by anecdotal
observations of mixed chimerism following conventional
transplantations for sickle cell disease [16].
In conclusion, establishment of mixed hematopoietic
chimerism in PK-deficient dogs using a nonmyeloablative
conditioning regimen and hematopoietic cell transplanta-
tion can be accomplished, but mixed chimerism, although it
reversed or delayed myeloﬁbrosis, was not sufﬁcient to com-
pletely eliminate hemolysis. Therefore, conversion to all-
donor chimerism appears to be necessary for a long-term
cure for hemolytic anemia due to PK deﬁciency.
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